A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

Trial Profile

A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Everolimus (Primary) ; Bicalutamide; Leuprorelin
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to withdrawn prior to recruitment.
    • 01 Oct 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 24 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top